Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase 1 dose-escalation data, cash-runway forecasts, and share-based compensation tables often stretch Nuvalent鈥檚 disclosures far beyond 200 pages. Finding where the company reports trial enrollment numbers or how much dilution new equity raises might cause can feel like searching for a molecule in a lab beaker. If you have ever typed 鈥淣uvalent insider trading Form 4 transactions鈥� into Google, you already know the challenge. That complexity is why investors need Nuvalent SEC filings explained simply, without losing the nuance that drives valuation for a clinical-stage oncology company.
Stock Titan鈥檚 AI tackles the hard chemistry of regulatory language. Our engine turns each Nuvalent annual report 10-K simplified and every Nuvalent quarterly earnings report 10-Q filing into plain-English briefs that spotlight pipeline progress, R&D spend, and cash-burn trends. AG真人官方-time alerts push Nuvalent Form 4 insider transactions real-time to your dashboard, so you can see Nuvalent executive stock transactions Form 4 within minutes of EDGAR posting. Interactive modules map 8-K material events to specific trial milestones, letting you skim Nuvalent 8-K material events explained instead of scrolling line by line.
Want deeper context? Click into any filing and our AI highlights where option grants appear in a Nuvalent proxy statement executive compensation section, or generates side-by-side Nuvalent earnings report filing analysis across quarters. You will also find:
- Segmented R&D spend tied to ALK, ROS1, and HER2 programs
- Cash-runway projections based on the latest 10-Q
- Insider purchase patterns before data readouts
Understanding Nuvalent SEC documents with AI means less time decoding tables and more time deciding if the next kinase-inhibitor breakthrough fits your portfolio. AG真人官方-time updates, comprehensive coverage, and expert analysis鈥攁ll in one place.
Nuvalent insider activity: option exercises and a planned sale under a 10b5-1 plan. Henry E. Pelish, Nuvalent's Chief Scientific Officer, acquired shares through option exercises and sold shares pursuant to a pre-established trading plan. On 08/07/2025 Pelish exercised options to acquire 731 shares at $18.93, 877 shares at $27.85 and 3,892 shares at $29.33, and sold 5,500 shares at $74.85. After these transactions his reported direct beneficial ownership is 60,956 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted November 1, 2024, and includes vesting schedules for the options.
Nuvalent, Inc. (NUVL) 鈥� Form 144 filing discloses a planned resale of 4,253 Class A common shares, valued at roughly $349,086, through Goldman Sachs & Co. LLC on or after 24 Jul 2025.
The shares were originally acquired in two public offerings (3,535 on 02 Aug 2021 and 718 on 03 Nov 2022) and equal just ~0.006% of the 66.4 million shares outstanding, implying negligible impact on float or dilution because Rule 144 covers already-issued stock. No sales have occurred in the past three months, and the seller certifies possession of no material non-public information.
The notice contains no operational or earnings data and does not involve new capital for the company; however, investors may view insider disposition鈥攁lbeit small鈥攁s a sentiment indicator to be weighed against broader fundamentals.
Nuvalent, Inc. (NUVL) Form 144 reports a planned insider sale of 156,670 Class A common shares, equal to roughly 0.24 % of the 66.37 million shares outstanding. The proposed transaction, to be executed through Goldman Sachs & Co. LLC, carries an aggregate market value of $12.86 million, implying a reference price near $82 per share. The approximate sale date listed is 24 July 2025 on Nasdaq.
The shares were originally acquired on 30 April 2021 via a purchase of preferred stock that automatically converted to common immediately prior to Nuvalent鈥檚 IPO. The filer reports no other share sales in the past three months and certifies that no undisclosed material adverse information is known.
While the notice signals insider intent to monetize a portion of holdings, the size is modest versus float and does not by itself alter Nuvalent鈥檚 operating outlook. Investors may monitor subsequent Form 4 filings for execution details and gauge any short-term supply effects.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
